Gibson PG, McDonald VM, Marks GB. Asthma in the older adult. Lancet. 2010;374(9743):803–13.CrossRef
McDonald VM, Simpson JL, Higgins I, et al. Multidimensional assessment of older people with asthma & COPD: clinical management and health status. Age Ageing. 2011;40(1):42–9.PubMedCrossRef
Cosio BG, Agusti A. Comorbidity: a distinctive feature of elderly respiratory patients. Eur Respir Mon. 2009;43:205–16.CrossRef
Hanania NA, King MJ, Braman SS, et al. Asthma in the elderly: current understanding and future research needs—a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011;128(3 Suppl):S4–24.PubMedCrossRef
McDonald VM, Gibson PG. Asthma mortality and management in older Australians: time for a new approach? Australas J Ageing. 2008;27:215.PubMedCrossRef
Australian Centre for Asthma Monitoring. Asthma in Australia 2008. Canberra: Australian Institute of Health and Welfare; 2008. Contract No.: Report No. ACM 14.
Navaratnam P, Jayawant SS, Pedersen CA, et al. Asthma pharmacotherapy prescribing in the ambulatory population of the United States: evidence of nonadherence to national guidelines and implications for elderly people. J Am Geriatr Soc. 2008;56(7):1312–7.PubMedCrossRef
Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010;182(7):673–8.PubMedCrossRef
Bednarek M, Maciejewski J, Wozniak M, et al. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63(5):402–7.PubMedCrossRef
Buist SA, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–50.PubMedCrossRef
Antonelli Incalzi R, Pedone C, Pahor M. Multidimensional assessment and treatment of the elderly with COPD. Eur Respir Mon. 2009(43):35–55.
Beasley R, Weatherall M, Travers J, et al. Time to define the disorders of the syndrome of COPD. Lancet. 2009;29:670–2.CrossRef
Guerra S. Asthma and chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol. 2009;9:409–16.PubMedCrossRef
Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–12.PubMedCrossRef
Marks GB, Poulos LM, Jenkins CR, et al. Asthma in older adults: a holistic, person centred and problem oriented approach. Med J Aust. 2009;191(4):197–9.PubMed
United Nations. Report of the Second World Assembly on Ageing. Madrid, Spain: United Nations; 2002.
Productivity Commission. Economic implications of an ageing Australia, research report. Canberra: Commonwealth of Australia; 2005.
Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross sectional surveys. Lancet. 2006;368(9537):733–43.PubMedCrossRef
Bellia V, Scichilone N, Battaglia S. Asthma in the elderly. Eur Respir Mon. 2009;43:56–76.CrossRef
Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging. 2006;1(3):253–60.PubMedCrossRef
Berend N. Normal ageing of the lung: implications for diagnosis and monitoring of asthma in older people. Med J Aust. 2005;183(1 Suppl):S28–9.PubMed
De Martinis M, Franceschi C, Monti D, et al. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005;579(10):2035–9.PubMedCrossRef
Meyer KC, Rosenthal NS, Sorergel P, et al. Neutrophils and low grade inflammation in the seemingly normal aging human lung. Mech Aging Dev. 1998;104(2):169–81.PubMedCrossRef
Thompson AB, Scholer SG, Daughton DM, et al. Altered epithelial lining fluid parameters in old normal individuals. J Gerontol. 1992;47(5):M171–6.PubMedCrossRef
Sharma G, Hanania NA, Shim YM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(7):573–80.PubMedCrossRef
Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple co-morbid diseases. J Am Med Assoc. 2005;294(6):716–24.CrossRef
Wilper AP, Woolhandler S, Lasser KE, et al. A national study of chronic disease prevalence and access to care in uninsured U.S. adults. Ann Intern Med. 2008;149(3):170–6.PubMedCrossRef
Boulet LP, Turcotte H, Turcot O, et al. Airway inflammation in asthma with incomplete reversibility of airflow obstruction. Respir Med. 2003;97:739–44.PubMedCrossRef
Mannino DM, Hole D, Gillis C, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(3):627–43.PubMedCrossRef
Fabbri L, Ferrari R. Chronic disease in the elderly: back to the future of internal medicine. Breathe. 2006;3:41–9.
Luppi F, Franco F, Beghé B, et al. Treatment of chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc. 2008;5:848–56.PubMedCrossRef
Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should). Proc Am Thorac Soc. 2007;4(7):522–5.PubMedCrossRef
Quinet P, Young CA, Héritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med. 2010;53(2):69–76.PubMedCrossRef
Janssens W, Vandenbrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83.PubMedCrossRef
Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–22.PubMedCrossRef
Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26.PubMedCrossRef
Banning M. Older people and adherence with medication: a review of the literature. Int J Nurs Stud. 2008;45(10):1550–61.PubMedCrossRef
Goeman DP, Douglass JA. Optimal management of asthma in elderly patients: strategies to improve adherence to recommended interventions. Drugs Aging. 2007;24(5):381–94.PubMedCrossRef
Vozoris NT, Stanbrook MB. Smoking prevalence, behaviours, and cessation among individuals with COPD or asthma. Respir Med. 2011;105(3):477–84.PubMedCrossRef
Gibson PG, Talbot PI, Toneguzzi RC. Self-management, autonomy, and quality of life in asthma. Chest. 1995;107(4):1003–8.PubMedCrossRef
Little P, Everitt H, Williamson I. Preferences of patients for patient centered approach to consultation in primary care: observational study. BMJ. 2001;322(7284):468–72.PubMedCrossRef
Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J. 2010;35(4):913–22.PubMedCrossRef
GINA. Global strategy for asthma management and prevention: NHLBI/WHO workshop report. Bethesda (MD): Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI); 2006.
Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of COPD 2006 Update. Am J Respir Crit Care Med. 2007;176:532–55.PubMedCrossRef
Gibson PG, Simpson JS. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64:728–35.PubMedCrossRef
Snider GL. Distinguishing among asthma, chronic bronchitis, and emphysema. Chest. 1985;87(1 Suppl):35S–9S.PubMed
American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:s77–121.
Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003;124:474–81.PubMedCrossRef
Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax. 2008;63:761–7.PubMedCrossRef
Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009;34(4):812–8.PubMedCrossRef
Vonk JM, Jongepier H, Panhuysen CIM, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 2003;58:322–7.PubMedCrossRef
Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659–64.PubMedCrossRef
Reid DW, Soltani A, Johns DP, et al. Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease. Intern Med J. 2003;33(12):572–7.PubMedCrossRef
Simpson JL, Scott R, Boyle M, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11:54–61.PubMedCrossRef
Gorska K, Krenke R, Korczynski P, et al. Eosinophilic airway inflammation in chronic obstructive pulmonary disease and asthma. J Physiol Pharmacol. 2008;59(Suppl 6):261–70.PubMed
Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906–13.PubMedCrossRef
Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148–55.PubMedCrossRef
Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy. 2009;39:1652–8.PubMedCrossRef
D’silva L, Cook RJ, Allen CJ, et al. Changing pattern of sputum cell counts during successive exacerbations of airway disease. Respir Med. 2007;101:2217–20.PubMedCrossRef
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease; 2011.
McKenzie DK, Abramson M, Crockett AJ, et al. The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2009. Brisbane: Australian Lung Foundation; 2009. http://www.copdx.org.au/guidelines/index.asp
. Accessed 3 Feb 2009.
Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–303.PubMedCrossRef
Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005;60(12):992–7.PubMedCrossRef
Gibson PG, Powell H, Coughlin J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database of Systematic Reviews. 2003;(3):CD001117.
Effing TW, Monninkhof EM, van der Valk PDLPM, et al. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2007;(4):CD002990.
Willemse BW, Postma DS, Timens W, et al. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J. 2004;23(3):464–76.PubMedCrossRef
Franceschi C, Bonafè M. Centenarians as a model for healthy aging. Biochem Soc Trans. 2003;31(2):457–61.PubMedCrossRef
Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;1(370):797–9.CrossRef
Agustí AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347–60.PubMedCrossRef
Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.PubMedCrossRef
Yokoyama A, Kohno N, Fujino S, et al. Circulating interleukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med. 1995;151(5):1354–8.PubMedCrossRef
Takemura M, Matsumoto H, Niimi A, et al. High sensitivity C-reactive protein in asthma. Eur Respir J. 2006;27(5):908–12.PubMed
Higashimoto Y, Yamagata Y, Taya S, et al. Systemic inflammation in chronic obstructive pulmonary disease and asthma: similarities and differences. Respirology. 2008;13:128–33.PubMed
Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Resp Med. 2004;98:99–107.CrossRef
Hurst JR, Wedzicha JA. The biology of a chronic obstructive pulmonary disease exacerbation. Clin Chest Med. 2007;28(3):525–36.PubMedCrossRef
Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85.PubMedCrossRef
Smith DJ, Yerkovich ST, Towers MA, et al. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J. 2011;37(3):516–22.PubMedCrossRef
Lopez-Campos J, Arellano E, Calero C, et al. Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays. BMC Med Res Methodol. 2012;12(1):40.PubMedCrossRef
Bozinovski S, Uddin M, Vlahos R, et al. Serum amyloid A opposes lipoxin A to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci USA. 2012;109(3):935–40.PubMedCrossRef
Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;23:23.
Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax. 2008;63(12):1058–63.
Verrills NM, Irwin JA, He XY, et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(12):1633–43.PubMedCrossRef
American Healthways, Johns Hopkins. Standard outcome metrics and evaluation outcome methodology for disease management programmes. Second Annual Disease Management Outcomes Summit; 2002 Nov 7–10; Palm Desert, CA. Franklin, TN: American Healthways; 2002.
Vitry AI, Zhang Y. Quality of Australian clinical guidelines and relevance to the care of older people with multiple comorbid conditions. Med J Aust. 2008;189(7):360–5.PubMed
Craig BM, Kraus CK, Chewning BA, et al. Quality of care for older adults with chronic obstructive pulmonary disease and asthma based on comparisons to practice guidelines and smoking status. BMC Health Serv Res. 2008;8:1–9.
Costantino G, Rusconi AM, Duca PG, et al. Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice. Intern Emerg Med. 2008;4(2):117–22.PubMedCrossRef
Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62(3):219–23.PubMedCrossRef
Travers J, Marsh S, Caldwell B, et al. External validity of randomized controlled trials in COPD. Respir Med. 2007;101(6):1313–20.PubMedCrossRef
Ware JH, Hamel MB. Pragmatic trials—guides to better patient care? N Engl J Med. 2011;364(18):1685–7.PubMedCrossRef
Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171–8.PubMedCrossRef
Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies. Clin Exp Allergy. 2009;39(4):478–90.PubMedCrossRef
Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011;378(9795):983–90.PubMedCrossRef
Hunter DJ, Fairfield G. Disease management. Br Med J. 1997;315(7099):50–3.CrossRef
Hunter DJ. Disease management: has it a future? It has a compelling logic, but needs to be tested in practice. Br Med J. 2000;320(7234):530.CrossRef
Solomon D, Brown SA, Brummel-Smith K, et al. Best paper of the 1980 s: National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. 1988. J Am Geriatr Soc. 2003;51(10):1490–4.PubMedCrossRef
Vliek S, Melis RJ, Faes M, et al. Single versus multicomponent intervention in frail elderly: simplicity or complexity as precondition for success? J Nutr Health Aging. 2008;12(5):319–22.PubMedCrossRef
Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342:1032–6.PubMedCrossRef
McDonald VM, Higgins I, Wood LG, et al. Multidimensional assessment and individualised management of obstructive airway diseases (OAD) in older adults. Respirology. 2011;16:13.CrossRef
Koff PB, Jones RH, Cashman JM, et al. Proactive integrated care improves quality of life in patients with COPD. Eur Respir J. 2009;33(5):1031–8.PubMedCrossRef
Rice KL, Dewan N, Bloomfield HE, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010;182(7):890–6.PubMedCrossRef
Reilly JJ. COPD and declining FEV1—time to divide and conquer? N Engl J Med. 2008;359:1616–8.PubMedCrossRef
McDonald VM, Higgins I, Simpson JL, et al. The importance of clinical management problems in older people with COPD and asthma: do patients and physicians agree? Prim Care Respir J. 2011;20(4):389–95.PubMedCrossRef
National Ageing Research Institute. What is person-centred health care? A literature review. Melbourne: Ageing and Complex Care, Continuing Care, Integrated Care, Wellbeing, Integrated Care and Ageing, Department of Health; 2006.
Bauman AE, Fardy HJ, Harris PG. Getting it right: why bother with patient-centered care? Med J Aust. 2003;179(5):253–6.PubMed
Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566–77.PubMedCrossRef
Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–93.PubMedCrossRef
Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;30:1715–21.CrossRef
Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27:483–94.PubMedCrossRef
Petsky HL, Kynaston JA, Turner C, et al. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews. 2007; (2): CD005603.
Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.PubMedCrossRef
Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139–47.PubMedCrossRef
He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010;80(6):445–52.PubMedCrossRef
Figueiredo Bde C, Ibiapina Cda C. The role of macrolides in noncystic fibrosis bronchiectasis. Pulm Med. 2011; 2011: 751982. doi:10.1155/2011/751982
Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749–56.PubMedCrossRef
Tateda K, Standiford TJ, Pechere JC, et al. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr Pharm Des. 2004;10:3055–65.PubMedCrossRef
López-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol. 2008;8:286–91.PubMedCrossRef
Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)—can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(2A):33A–41A.PubMedCrossRef
Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8.PubMedCrossRef
Lee T-M, Lin M-S, Chang N-C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008;101(4):530–5.PubMedCrossRef
Suissa S. Co-morbidity in COPD: the effects of cardiovascular drug therapies. Respiration. 2010;80(1):3–7.PubMedCrossRef
Lee T-M, Chen C–C, Shen H-N, et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci. 2009;116(6):497–505.PubMedCrossRef
Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62(9):1373–8.PubMedCrossRef
Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest. 2007;132(6):1764–71.PubMedCrossRef
Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–60.PubMedCrossRef
Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006–12.PubMedCrossRef
Ishida W, Kajiwara T, Taneichi H, et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med. 2007;212(3):265–73.PubMedCrossRef
van Gestel YRBM, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008;102(2):192–6.PubMedCrossRef
Ulrik CS, von Linstow ML, Nepper-Christensen S, Porsbjerg C, Backer V. Chronic mucus hypersecretion: a marker of asthma in young adults. Respir Med. 2005;99:1576–82.
Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76.PubMedCrossRef
Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007;52:1176–93.PubMed
Henke MO, Shah SA, Rubin BK. The role of airway secretions in COPD—clinical applications. COPD. 2005;2:377–90.PubMedCrossRef
Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–40.PubMedCrossRef
Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews. 2009;(2): CD001506.
Pavia D, Thomson ML, Clarke SW. Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am J Respir Crit Care Med. 1978;117:199–203.
Clarke SW, Lopez-Vidriero MT, Pavia D, et al. The effect of sodium 2-mercapto-ethane sulphonate and hypertonic saline aerosols on bronchial clearance in chronic bronchitis. Br J Clin Pharmacol. 1979;7:39–44.PubMedCrossRef
Daviskas E, Anderson SD, Young IH. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. Respirology. 2007;12(5):683–91.PubMedCrossRef
Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database of Systematic Reviews. 2006;(2): CD002996.
Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(12):1259–65.PubMedCrossRef
Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–9.PubMedCrossRef
Shamsham F, Mitchell J. Essentials of the diagnosis of heart failure. Fam Physician. 2000;61:1319–28.
Roth SM, Metter EJ, Ling S, et al. Inflammatory factors in age-related muscle wasting. Curr Opin Rheumatol. 2006;18:625–30.PubMedCrossRef
Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147:1151–6.PubMedCrossRef
Mostert R, Goris A, Weling-Scheepers C, et al. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med. 2000;94(4):859–67.PubMedCrossRef
Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–7.PubMedCrossRef
Oreopoulos A, Kalantar-Zadeh K, Sharma AM, et al. The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med. 2009;24(4):643–59.CrossRef
Losonczy KG, Harris TB, Cornoni-Huntley J, et al. Does weight loss from middle age to old age explain the inverse weight mortality relation in old age? Am J Epidemiol. 1995;141(4):312–21.PubMedCrossRef
Grabowski DC, Ellis JE. High body mass index does not predict mortality in older people: analysis of the Longitudinal Study of Aging. J Am Geriatr Soc. 2001;49(7):968–79.PubMedCrossRef
Villareal DT, Apovian CM, Kushner RF, et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr. 2005;82(5):923–34.PubMed
Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest. 2003;123(5):1460–6.PubMedCrossRef
Landbo C, Prescott E, Lange PT, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1856–61.PubMedCrossRef
Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–12.PubMedCrossRef
Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791–7.PubMedCrossRef
Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197–209.PubMedCrossRef
Flicker L, McCaul KA, Hankey GJ, et al. Body mass index and survival in men and women aged 70 to 75. J Am Geriatr Soc. 2010;58(2):234–41.PubMedCrossRef
Franssen FME, O’Donnell DE, Goossens GH, et al. Obesity and the lung: 5. Obesity and COPD. Thorax. 2008;63:1110–7.PubMedCrossRef
Steuten LM, Creutzberg EC, Vrijhoef HJ, et al. COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J. 2006;15:84–91.PubMedCrossRef
Eisner MD, Blanc PD, Sidney S, et al. Body composition and functional limitation in COPD. Respir Res. 2007;8:7.PubMedCrossRef
Aronson D, Bartha P, Zinder O, et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord. 2004;28:674–9.PubMedCrossRef
Florez H, Castillo-Florez S, Mendez A, et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract. 2006;71:92–100.PubMedCrossRef
Vandenbergh E, Van de Woestijne KP, Gyselen A. Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. Am Rev Respir Dis. 1967;95:556–66.PubMed
Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:322–3.CrossRef
Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27(3):495–503.PubMedCrossRef
Wood LG, Gibson PG. Dietary factors lead to innate immune activation in asthma. Pharmacol Ther. 2009;123(1):37–53.PubMedCrossRef
Harrington JJ, Lee-Chiong T Jr. Sleep and older patients. Clin Chest Med. 2007;28(4):673–84.PubMedCrossRef
Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18(6):425–32.PubMed
Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33(4):897–906.PubMedCrossRef
Zamarrón C, García Paz V, Morete E, et al. Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences. Int J Chron Obstruct Pulmon Dis. 2008;3(4):671–82.
Jorgensen NR, Schwarz P, Holme I, et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease—a cross sectional study. Respir Med. 2007;101:177–85.PubMedCrossRef
Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345(13):941–7.PubMedCrossRef
Ip M, Lam K, Yam L, et al. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest. 1994;105(6):1722–7.PubMedCrossRef
Cote C, Zilberberg MD, Mody SH, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29(5):923–9.PubMedCrossRef
Kvaal K, Macijauskiene J, Engedal K, et al. High prevalence of anxiety symptoms in hospitalized geriatric patients. Int J Geriatr Psychiatry. 2001;16(7):690–3.PubMedCrossRef
Cafarella PA, Effing TW, Usmani ZA, et al. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology. 2012;17(4):627–38.PubMedCrossRef
Yohannes AM, Baldwin RC, Connolly MJ. Prevalence of sub-threshold depression in elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2003;18(5):412–6.PubMedCrossRef
Kim HF, Kunik ME, Molinari VA, et al. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics. 2000;41(6):465–71.PubMedCrossRef
Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127(4):1205–11.PubMedCrossRef
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–7.PubMedCrossRef
Yohannes AM, Baldwin RC, Connolly MJ. Predictors of 1-year mortality in patients discharged from hospital following acute exacerbation of chronic obstructive pulmonary disease. Age Ageing. 2005;34(5):491–6.PubMedCrossRef
Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4 Suppl):43S–56S.PubMedCrossRef
Rennard SI, Farmer SG. Exacerbations and progression of disease in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(2):88–92.PubMedCrossRef
Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(5):369–74.PubMedCrossRef
Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30(3):452–6.PubMedCrossRef
Clarke SW. Management of mucus hypersecretion. Eur Resp J. 1987;136–44:153.
Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530–5.PubMedCrossRef
Rogers DF. Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol. 2004;4(3):241–50.PubMedCrossRef
Roche N. Activity limitation: a major consequence of dyspnoea in COPD. Eur Respir Rev. 2009;18(112):54–7.PubMedCrossRef
Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972–7.PubMedCrossRef
Schönhofer B, Ardes P, Geibel M, et al. Evaluation of a movement detector to measure daily activity in patients with chronic lung disease. Eur Respir J. 1997;10(12):2814–9.PubMedCrossRef
Jones PW. Activity limitation and quality of life in COPD. COPD. 2007;4(3):273–8.PubMedCrossRef
Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007;175(5):458–63.PubMedCrossRef
Strine TW, Balluz LS, Ford ES. The associations between smoking, physical inactivity, obesity, and asthma severity in the general US population. J Asthma. 2008;44(8):651–8.CrossRef
Sherriff A, Maitra A, Ness AR, et al. Association of duration of television viewing in early childhood with the subsequent development of asthma. Thorax. 2009;64(4):321–5.PubMedCrossRef
Rasmussen F, Lambrechtsen J, Siersted HC, et al. Low physical fitness in childhood is associated with the development of asthma in young adulthood: the Odense Schoolchild Study. Eur Respir J. 2000;16(5):866–70.PubMedCrossRef
Virchow JC, Crompton GK. Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102:10–9.PubMedCrossRef
Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75(1):18–25.PubMedCrossRef
Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age. Int J Clin Pract. 2009;63(8):1150–3.PubMedCrossRef
Board M, Allen SC. A simple drawing test to identify patients who are unlikely to be able to learn to use an inhaler. Int J Clin Pract. 2006;60(5):510–3.PubMedCrossRef
Quinet P, Young CA, Héritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med. 2010;53(2):69–76.PubMedCrossRef
MacLaughlin EJ, Raehl CL, Treadway AK, et al. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging. 2005;22(3):231–55.PubMedCrossRef
Rand CS. Patient adherence with COPD therapy. Eur Respir Rev. 2005;14(96):97–101.CrossRef
Bozek A, Jarzab J. Adherence to asthma therapy in elderly patients. J Asthma. 2010;47(2):162–5.PubMedCrossRef
DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–9.PubMedCrossRef
Horne R. Compliance, adherence, and concordance—implications for asthma treatment. Chest. 2006;130(1 Suppl):65S–72S.PubMedCrossRef
Jenkins L, Britten N, Stevenson F, et al. Developing and using quantitative instruments for measuring doctor-patient communication about drugs. Patient Educ Couns. 2003;50(3):273–8.PubMedCrossRef
Irwin RS, Richardson ND. Patient-Focused Care; using the right tools. Chest. 2006;130:73S–82S.PubMedCrossRef
Marin L, Colombo P, Bebawy M, et al. Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv. 2011;8(9):1205–20.PubMedCrossRef
Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews. 2008;(1):CD000146.
Jimenez Ruiz CA, Ramos Pinedo A, Cicero Guerrero A, et al. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res. 2012;17:17.
Pesek R, Lockey R. Vaccination of adults with asthma and COPD. Allergy. 2011;66(1):25–31.PubMedCrossRef